We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
-27.59%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$2.52B
AUM Growth
-$1.03B
Cap. Flow
+$32.7M
Cap. Flow %
1.3%
Top 10 Hldgs %
75.05%
Holding
30
New
–
Increased
10
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$10.2M
2
INCY icon
Incyte
INCY
+$6.71M
3
SAGE
Sage Therapeutics
SAGE
+$4.4M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$3.91M
5
HALO icon
Halozyme
HALO
+$3.29M

Top Sells

Rank Stock Value
1
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$3.67M
2
PTCT icon
PTC Therapeutics
PTCT
+$2.08M

Sector Composition

Rank Sector Weight
1 Healthcare 86.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLVS
26
DELISTED
Clovis Oncology, Inc.
CLVS
$10.1M 0.4%
528,188
– –
ACHN
27
DELISTED
Achillion Pharmaceuticals
ACHN
$9.88M 0.39%
1,279,340
– –
CDTX
28
DELISTED
Cidara Therapeutics
CDTX
$9.48M 0.38%
37,341
+14,007
+60% +$3.23M
PTCT icon
29
PTC Therapeutics
PTCT
$6.12B
$7.62M 0.3%
1,182,912
-120,000
-9% -$2.08M
TTPH
30
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
– –
-18,310
Closed -$3.67M
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 10.02% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 17.19% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q1 2016 Portfolio in Review

As of Q1 2016, BB Biotech held 30 positions worth $2.52B, down 29% from $3.55B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Trading was light in Q1 2016: portfolio turnover was 3.3%. BB Biotech opened no new positions and exited 1, leaving the 30-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 86% a quarter earlier.

  • BB Biotech added most to Ionis Pharmaceuticals in Q1 2016, an estimated $10.2M increase.
  • BB Biotech's biggest Q1 2016 reduction was PTC Therapeutics, cutting an estimated $2.08M.
  • BB Biotech fully exited Tetraphase Pharmaceuticals, Inc. in Q1 2016, selling an estimated $3.67M.
  • BB Biotech's ten largest holdings make up 75% of its $2.52B portfolio in Q1 2016.
  • BB Biotech opened 0 new positions and closed 1 in Q1 2016.
  • BB Biotech's portfolio value fell 29% quarter-over-quarter to $2.52B.

Based on BB Biotech's 13F filing for Q1 2016, filed 12 May 2016.